Sugar with your protein? - Generation of a fucosylation-deficient CHO cell host to produce therapeutics with enhanced potency

Monoclonal antibodies (mAbs) are highly specific, stable molecules with long half-lives and ability to interact and modulate different elements of the immune system. Because of these properties mAbs have become a leading class of therapeutics in the treatment of a growing number of different disease areas from autoimmune diseases to neurological pathologies, infectious diseases, or cancer. Their versatility and the progress made in discovery and re-engineering of these molecules leading to improved therapeutic efficacy, have made them very successful with global revenue approaching 70% of total sales of biopharmaceuticals.

In this whitepaper we take a look at the challenges in manufacturing these mAbs and the heavy investments biopharmaceutical companies have made into their research and development programs in an effort to improve their product quality and consistency.

Covering areas including:

• How to increase productivity whilst controlling product quality
• The importance of glycosylation in proteins
• The tools available to biopharmaceutical companies
• Generation of a cell host to produce fully afucosylated therapeutics

For research use only. Not for use in diagnostic procedures.